Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen
Charles G. Drake(Columbia University Irving Medical Center), William G. Nelson(Johns Hopkins University), Edward L. Hipkiss(Sidney Kimmel Comprehensive Cancer Center), Erin S. Kelleher(University of Houston), Dallas B. Flies(Mayo Clinic in Arizona), Lee Coryell(UConn Health), Drew M. Pardoll(Bloomberg (United States)), Amy D. H. Doody(UConn Health), Eugene P. Kennedy(Chevron (Australia)), Meixiao Long(The Ohio State University), Patrick W. McGary(UConn Health), Marianne A. Mihalyo(UConn Health), Ching-Tai Huang(Sidney Kimmel Comprehensive Cancer Center)
Cited by 287
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
|Nature Medicine|2002|5.1k